. Author manuscript; available in PMC: 2015 May 27.

Published in final edited form as: Cancer. 2009 Feb 1;115(3):551–560. doi: 10.1002/cncr.24066

Table 2.

Reasons for Dose Escalation of Imatinib Among Patients Randomized to Receive Imatinib in the International Randomized Study of Interferon and STI571 Study

IRIS Protocol Criteria (n539)^*		ELN Recommendations (n548)^*
Reason	No. (%)	Reason	No. (%)
No CHR at 3 mo	7 (18)	3 mo: Failure or suboptimal response (no HR or CHR)	7 (15)
No MinCyR at 12mo	8 (21)	6 mo: Failure (no CHR, no CyR)	1 (2)
Loss of MCyR	18 (46)	12 mo: Suboptimal response (no CCyR)	4 (8)
Progression^†	6 (15)	12 mo: Failure (no MCyR)	11 (23)
		18 mo: Failure (no CCyR)	10 (21)
		Failure at anytime (confirmed loss of CHR or loss of CCyR)	15 (31)

IRIS indicates the International Randomized Study of Interferon and STI571 trial; ELN, European LeukemiaNet; CHR, complete hematologic response; HR, hematologic response; MinCyR, minimal cytogenetic response; CyR, cytogenetic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response.

Includes 34 patients who met both ELN and IRIS protocol criteria for dose escalation,

^†

A subset of patients with disease progression was included in the “per IRIS Protocol Criteria” analysis, because the prescribing information for imatinib allows for dose escalation for this reason.